Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD

Sanofi and Regeneron Pharmaceuticals, Inc. appear well positioned to add a new blockbuster-sized indication to labeling for Dupixent (dupilumab) in patients with chronic obstructive pulmonary disease (COPD), a challenging respiratory condition for which no other biologic drugs have been approved.

The companies reported positive data from the Phase III BOREAS trial testing Dupixent in patients with COPD on 23 March, surpassing the expectations of investors who viewed the chance of success as uncertain given failed attempts by other biologic drug manufacturers to expand into the disease